Current clinical studies featuring anti-VEGF treatment investigate its efficacy in combination with hypofractionated radiotherapy in patients with recurrent GBM (ClinicalTrials.gov identifier NCT01730950). This evidence concerns the gene VEGFA and glioblastoma.